AzTrials
AzTrials

Mitral Valve ProlapseSCIMITARNCT06341166

Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse

An observational study of Mitral Valve Prolapse, run by Centro Cardiologico Monzino at 1 site in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a multicenter, observational prospective and retrospective study which aims are: 1) to compute a scoring model potentially predictive for the diagnosis of fibrosis by CMR in patients with MVP; 2) to identify specific features that may predispose to ≥ mild VAs or SCD in patients with MVP. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Mitral Valve Prolapse
How many people
300 participants
Where
1 siteItaly
Study dates
19 Jun 2023to 19 Oct 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with a diagnosis of mitral valve prolapse by transthoracic echocardiography, independent of mitral regurgitation grade, either affected by Barlow's disease, fibroelastic deficiency, forme frustae of mitral valve prolapse.

Who may be able to join

  • age ≥ 18 years
  • Echocardiographic diagnosis of mitral valve prolaspe, defined as a systolic displacement of one or both mitral leaflets ≥ 2 mm above the plane of the mitral valve annulus in long-axis views

Who cannot join

  • age< 18 years
  • coexistence of other cardiomyopathies or other ≥ moderate valve diseases
  • scarce acoustic transthoracic echocardiographic window
  • usual contraindications for cardiac magnetic resonance

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Italy1 site, 1 recruiting
  • Centro Cardiologico Monzino

    Milan, Milan, 20131

    Chiara Centenaro, 0258002031 ext. +39, chiara.centenaro@cardiologicomonzino.it

    Recruiting

Other trials in Italy

About this study

Official title: Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse: the SCIMITAR Trial

This is a multicenter, observational prospective and retrospective study which aims are: 1) to compute a scoring model potentially predictive for the diagnosis of fibrosis by CMR in patients with MVP; 2) to identify specific features that may predispose to ≥ mild VAs or SCD in patients with MVP.

Read the detailed description

Patients with mitral valve prolapse and non-significant mitral regurgitation generally have a good prognosis. A minority of patients with MVP suffers from ventricular arrhythmias. Different demographic, clinical, and electrocardiographic characteristics, as well as morphological and structural features of the MV were described as potential risk factors for ventricular arrhythmias, among which fibrosis of the left ventricular inferolateral wall and posterior papillary muscle as detected by cardiac magnetic resonance.

As cardiac magnetic resonance has some limitations, it is unknown if and which patients with mitral valve prolapse should undergo cardiac magnetic resonance in routine clinical practice, to search for late gadolinium enhancement as a surrogate for myocardial fibrosis.

Medical subject headings
Mitral Valve Prolapse

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06341166
Study groupRoleWhat they receive
Prospective CohortProspectively enrolled patients will undergo a complete assessment, as clinically indicated, including clinical evaluation, TTE, rest ECG, 24h ECG-monitoring, and CMR. CMR will be performed no more than 6 months apart from other examinations (TTE, rest ECG, 24h ECG-monitoring).
Retrospective CohortPatients will be enrolled retrospectively, in case they have already performed all examinations between 2016 and 2023

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Prediction of fibrosis by CMR

    Clinical, echocardiographic, electrocardiographic, and 24h-ECG monitoring variables will be collected in order to identify potential predictors of fibrosis as detected by cardiac magnetic resonance (CMR).

    Specifically, the following parameters will be collected.

    • Clinical data:
    • Transthoracic echocardiography parameters:
    • Rest ECG parameters:
    • 24h electrocardiographic monitoring parameters:
    • Ventricular arrhythmias (VAs) will be classified as suggested in the recently published EHRA consensus statement
    • CMR parameters, applying the protocol of the Society of Cardiovascular Magnetic Resonance

    Measured: June 2026

Secondary outcomes (6)
  1. Prediction of ≥ mild Ventricular Arrhythmias and/or Sudden cardiac death in mitral valve

    Clinical, echocardiographic, electrocardiographic, and CMR variables will be collected in order to identify potential predictors of ≥mild VAs, as defined by the recently published EHRA consensus document.

    An accurate description of these variables and the Units of Measure are the same as those reported in the section "Primary Outcome Measures".

    Measured: June 2026

  2. Clinical data

    • gender (female/male), and age in years;
    • family history for sudden cardiac death;
    • previous documentation of supraventricular and/or ventricular arrhythmias (VAs);
    • previous secondary prevention ICD implantation, previous transcatheter ablation of VAs;
    • symptoms (history of unexplained syncope/pre-syncope, palpitations, dyspnea, chest pain);
    • signs (mid-systolic click, murmurs of mitral regurgitation);
    • use of anti-arrhythmic drugs and/or beta-blockers.

    Measured: June 2026

  3. Transthoracic echocardiography parameters:

    • left atrial biplane volume in mL/m2;
    • presence, localization, and end-systolic measurement in millimeters of mitral annular disjunction (MAD);
    • mitral leaflet thickness in millimeters, presence of bileaflet prolapse;
    • mitral regurgitation (MR) grade, quantified by integrating qualitative and quantitative criteria according to the European guidelines;
    • left ventricular (LV) diameters in millimeters, volumes in mL/m2, and ejection fraction in %;
    • presence of curling of the posterolateral LV wall;
    • presence of the Pickelhaube sign at tissue Doppler imaging;
    • right ventricular end-diastolic area in cm2/m2, TAPSE in millimeters, and fractional area change in %;
    • systolic pulmonary artery pressure in mmHg, derived from the peak velocity of the tricuspid regurgitation and from the estimated right atrial pressure.

    Measured: June 2026

  4. Rest ECG parameters:

    • baseline rhythm (sinus rhythm, atrial fibrillation/flutter, junctional rhythm);
    • PQ and QRS intervals in milliseconds;
    • T wave inversion or biphasic T waves in the inferior and lateral leads;
    • QTc interval in milliseconds;
    • occurrence of premature supraventricular complexes;
    • occurrence of premature ventricular complexes (PVCs).

    Measured: June 2026

  5. 24h electrocardiographic monitoring parameters:

    • baseline rhythm (sinus rhythm, atrial fibrillation/flutter, junctional rhythm);
    • frequency (expressed in absolute number and as percentage of total beats number), and repetitiveness of premature supraventricular complexes;
    • occurrence of atrial fibrillation;
    • frequency (expressed in absolute number and as percentage of total beats number), and repetitiveness of PVCs.

    Ventricular arrhythmias (VAs) will be classified as suggested in the recently published EHRA consensus statement:

    • MILD VAs, defined as ≥ 5% total PVC burden or non-sustained (< 30 seconds) ventricular tachycardia (VT) runs with a heart rate < 120 bpm
    • MODERATE VAs, defined as non-sustained (< 30 seconds) VT runs with a heart rate of 120-179 bpm
    • SEVERE VAs, defined as non-sustained (< 30 seconds) VT runs with a heart rate > 180 bpm or sustained (≥ 30 seconds) VT/ventricular fibrillation.

    Measured: June 2026

  6. CMR parameters

    • MR grade (based on the regurgitant volume and regurgitant fraction);
    • LV mass in g/m2;
    • biventricular volumes in mL/m2, stroke volumes in mL, and ejection fraction in %;
    • presence of curling of the posterolateral LV wall;
    • presence, localization, end-systolic and end-diastolic measurement in millimeters of MAD;
    • presence and distribution of LGE.

    Measured: June 2026

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Apr 2024
  2. Study start19 Jun 2023
  3. Primary completion19 Oct 2026 (estimated)
  4. Study completion19 Oct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06341166
Sponsor's protocol ID
CCM1959
Acronym
SCIMITAR
Status last verified
Jan 2026
First submitted
14 Mar 2024
Last updated
21 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Mitral Valve Prolapse, run by Centro Cardiologico Monzino at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Gianluca Pontone, MD (0258002574 ext. +39, gianluca.pontone@cardiologicomonzino.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Prediction of fibrosis by CMR (time frame: June 2026). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in